Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing Klebsiella pneumoniae Under Antibiotic Selection Pressure

References

• Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115–20. doi:10.1128/CMR.00115-20
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-Avibactam: a Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Clin Ther. 2016;38(3):431–444. doi:10.1016/j.clinthera.2016.01.018
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 2019;6(12):ofz522. doi:10.1093/ofid/ofz522
   PubMed Web of Science ®Google Scholar
• Strich JR, Ricotta E, Warner S, et al. Pharmacoepidemiology of ceftazidime-avibactam use: a retrospective cohort analysis of 210 US hospitals. Clin Infect Dis. 2021;72(4):611–621. doi:10.1093/cid/ciaa061
   Web of Science ®Google Scholar
• Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Is ceftazidime/avibactam an option for serious infections due to extended-spectrum-β-lactamase- and AmpC-producing Enterobacterales?: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2020;65(1):e01052–20. doi:10.1128/AAC.01052-20
   Web of Science ®Google Scholar
• Dietl B, Martínez LM, Calbo E, Garau J. Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiol. 2020;15(7):473–484. doi:10.2217/fmb-2020-0012
   Web of Science ®Google Scholar
• Mirzaie A, Ranjbar R. Antibiotic resistance, virulence-associated genes analysis and molecular typing of Klebsiella pneumoniae strains recovered from clinical samples. AMB Express. 2021;11(1):122. doi:10.1186/s13568-021-01282-w
   Web of Science ®Google Scholar
• Ahmadi M, Ranjbar R, Behzadi P, et al. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella pneumoniae. Expert Rev Anti Infect Ther. 2022;20(3):463–472. doi:10.1080/14787210.2022.1990040
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao G, Chao X, Xie L, Wang H. The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020;17(17):6278. doi:10.3390/ijerph17176278
   PubMed Web of Science ®Google Scholar
• Zhen X, Stålsby Lundborg C, Sun X, Zhu N, Gu S, Dong H. Economic burden of antibiotic resistance in China: a national level estimate for inpatients. Antimicrob Resist Infect Control. 2021;10(1):5. doi:10.1186/s13756-020-00872-w
   PubMed Web of Science ®Google Scholar
• Zong Z, Wu A, Hu B. Infection control in the era of antimicrobial resistance in China: progress, challenges, and opportunities. Clin Infect Dis. 2020;71(Suppl 4):S372–S378. doi:10.1093/cid/ciaa1514
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection. 2020;48(6):835–851. doi:10.1007/s15010-020-01520-6
   PubMed Web of Science ®Google Scholar
• Coppi M, Di Pilato V, Monaco F, Giani T, Conaldi PG, Rossolini GM. Ceftazidime-avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258 Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(4):e01816–19. doi:10.1128/AAC.01816-19
   Google Scholar
• Humphries RM, Ambler J, Mitchell SL, et al. CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests. J Clin Microbiol. 2018;56(4):e01934–17. doi:10.1128/JCM.01934-17
   PubMed Web of Science ®Google Scholar
• Ding L, Shi Q, Han R, et al. Comparison of four carbapenemase detection methods for blaKPC-2 variants. Microbiol Spectr. 2021;9(3):e0095421. doi:10.1128/Spectrum.00954-21
   Google Scholar
• Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65(3):490–495. doi:10.1093/jac/dkp498
   PubMed Web of Science ®Google Scholar
• Tan D, Zhang Y, Cheng M, et al. Characterization of Klebsiella pneumoniae ST11 isolates and their interactions with lytic phages. Viruses. 2019;11(11):1080. doi:10.3390/v11111080
   PubMed Web of Science ®Google Scholar
• Nelson K, Hemarajata P, Sun D, et al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother. 2017;61(10):e00989–17. doi:10.1128/AAC.00989-17
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097–16. doi:10.1128/AAC.02097-16
   PubMed Web of Science ®Google Scholar
• Li D, Li K, Dong H, et al. Ceftazidime-avibactam resistance in Klebsiella pneumoniae sequence type 11 due to a mutation in plasmid-borne blakpc-2 to blakpc-33, in Henan, China. Infect Drug Resist. 2021;14:1725–1731. doi:10.2147/IDR.S306095
   PubMed Web of Science ®Google Scholar
• Galani I, Karaiskos I, Angelidis E, et al. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis. 2021;40(1):219–224. doi:10.1007/s10096-020-04000-9
   PubMed Web of Science ®Google Scholar
• Bianco G, Boattini M, Iannaccone M, et al. Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: a 2-year experience. J Glob Antimicrob Resist. 2021;24:411–414. doi:10.1016/j.jgar.2021.02.008
   PubMed Web of Science ®Google Scholar
• Niu S, Chavda KD, Wei J, et al. A ceftazidime-avibactam-resistant and carbapenem-susceptible Klebsiella pneumoniae strain harboring blaKPC-14 isolated in New York City. mSphere. 2020;5(4):e00775–20. doi:10.1128/mSphere.00775-20
   PubMed Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother. 2015;70(8):2279–2286. doi:10.1093/jac/dkv094
   PubMed Web of Science ®Google Scholar